Martha Sajatovic, MD

University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio

  • 21Articles
  • 109KReads1
  • 1999–2026Active
  • 100Collaborators
  • 678Citations2

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

About

Martha Sajatovic, MD, is affiliated with University Hospitals Cleveland Medical Center and Case Western Reserve University School of Medicine in Cleveland, Ohio. Since 1999, Dr. Sajatovic has published extensively on topics including bipolar disorder, schizophrenia and schizoaffective disorders, tardive dyskinesia, child and adolescent psychiatry, depression, geriatric psychiatry, mood disorders, and neurology. Her work covers clinical applications of long-acting injectable antipsychotics, treatment adherence strategies, and assessments related to movement disorders. Dr. Sajatovic has collaborated frequently with authors such as Christoph U. Correll and Joseph F. Goldberg.

Publications

JCP
Outcomes and Practice Patterns of LAI Versus Oral Antipsychotics Among Patients With Bipolar I Disorder in the US
Original Research

Outcomes and Practice Patterns of LAI Versus Oral Antipsychotics Among Patients With Bipolar I Disorder in the US

March 2, 2026

Long-acting injectable antipsychotics, especially second-generation formulations, are associated with reduced rehospitalization in bipolar I disorder compared to oral antipsychotics.
, , , et al
JCP
Clinical Application of Aripiprazole Monohydrate Long-Acting Injectables for the Treatment of Bipolar Type I Disorder: A Consensus Panel Report
Academic Highlights

Clinical Application of Aripiprazole Monohydrate Long-Acting Injectables for the Treatment of Bipolar Type I Disorder: A Consensus Panel Report

August 13, 2025

A consensus panel reviews treatment considerations in the use of long-acting injectable aripiprazole monohydrate in bipolar type I disorder.
, , , et al
JCP
Clinical Application of Aripiprazole Monohydrate Long-Acting Injectables for the Treatment of Schizophrenia: A Consensus Panel Report
Academic Highlights

Clinical Application of Aripiprazole Monohydrate Long-Acting Injectables for the Treatment of Schizophrenia: A Consensus Panel Report

August 13, 2025

A consensus panel reviews treatment considerations in the use of long-acting injectable aripiprazole monohydrate in schizophrenia.
, , , et al
JCP
Optimizing Treatment With Aripiprazole Monohydrate: Pharmacokinetic Advantages of Long-Acting Injectable Formulations, A Consensus Panel Report
Academic Highlights

Optimizing Treatment With Aripiprazole Monohydrate: Pharmacokinetic Advantages of Long-Acting Injectable Formulations, A Consensus Panel Report

June 13, 2025

A consensus panel reviews the pharmacokinetic advantages and clinical utility of long-acting injectable aripiprazole monohydrate to optimize treatment for schizophrenia and bipolar I disorder.
, , , et al
JCP
Valbenazine in Elderly Adults With Tardive Dyskinesia
Original Research

Valbenazine in Elderly Adults With Tardive Dyskinesia

April 23, 2025

In elderly adults who received up to 48 weeks of treatment, long-term valbenazine treatment led to substantial and sustained improvements in tardive dyskinesia according to clinician assessment and patient...
, , , et al
JCP
Earlier Use of Paliperidone Palmitate in Patients With Schizophrenia
Original Research

Earlier Use of Paliperidone Palmitate in Patients With Schizophrenia

September 25, 2023

Long-acting injectable antipsychotics (LAIs) are typically reserved for patients with a long history of schizophrenia. This analysis of 3 studies found benefit in initiating the LAI paliperidone palmitate earlier...
, , , et al
PCC
Original Research

Long-Acting Injectable Antipsychotic Plus Customized Adherence Enhancement

September 16, 2021

Medication adherence is often difficult in bipolar patients. This trial combined a behavioral customized adherence enhancement approach with long-acting injectable antipsychotics and assessed effects on adherence, symptoms, and functional...
, , , et al
JCP
Consensus Statement

Screening, Diagnosis, and Treatment of Tardive Dyskinesia

January 28, 2020

Tardive dyskinesia remains a serious complication associated with dopamine receptor blocking agents. In this article, read guidance from experts on best practices for tardive dyskinesia screening, diagnosis, and treatment.
, , , et al
JCP
Original Research

Customized Adherence Enhancement for Bipolar Disorder

September 25, 2018

Treatment nonadherence is bipolar disorder ranges from 20% to 60%. Read this article to learn how customized adherence enhancement (CAE)—a brief, bipolar disorder-specific approach that targets individual adherence barriers—compared...
, , , et al
JCP
Consensus Statement

Revisiting the Use of the AIMS in Tardive Dyskinesia Trials

May 8, 2018

The authors of this consensus statement look at the history of the use of the Abnormal Involuntary Movement Scale in tardive dyskinesia studies and outline the challenges of using...
, , , et al
JCP
Review Article

Youth With Autism in the Emergency Department

May 8, 2018

Families living with autism may use the emergency department to manage crises related to a variety of factors. This review summarizes current research relating to ED visits among youth...
, , , et al
JCP
Original Research

Lurasidone in Older Adults With Bipolar Depression

October 26, 2016

Lurasidone's favorable safety profile in younger adults suggests it would be a good candidate for the treatment of episodes of bipolar depression in older adults. For your patients 55...
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Ketamine and Psychedelics

Listen to the Podcast
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe